The 2020 edition of the CSCO Gastric Cancer Treatment Guide was released heavily, and the NavuliU single anti-I grade recommendation was included in the guidelines.

August 8, 2020, by the Chinese Society of Clinical Oncology (CSCO), Guangdong Provincial Institute of Health Management and Sun Yat-sen University affiliated oncology hospital co-sponsored the "2020 edition of CSCO gastric cancer diagnosis and treatment guide" online release and the first tour held in the cloud grand, the meeting for the first time exposed the 2020 edition of the "CSCO gastric cancer diagnosis and treatment guide" update points, Among them, the updated recommendation of immunotherapy became the biggest bright spot, based on THETRACTION-2 research results, following the approval of Navliu monotherapy by the State Drug Administration (NMPA) domestic market, the new version of the Guidelines Navulyu monotherapy as a third-line treatment option for patients with advanced metastatic gastric cancer was increased from II.
, Navuliu monotogenicbecametobecame the first approved immunocheckpoint inhibitor for the third-line treatment of advanced metastatic gastric cancer, also marks its official emergence as the standard treatment for advanced metastatic gastric cancer.
in recent years, the progress of immunotherapy in the field of gastric cancer has been evident, and based on the results of ATTRACTION-2 and KEYNOTE-059, the CSCO Guidelines for the Diagnosis and Treatment of Gastric Cancer will be available from the 2018 edition. -1 is included in the recommendation of third-line therapy, the recommended level is III.level, and the excellent data of the 2nd year follow-up of the ATTRACTION-2 study at the 2018 ESMO Annual Meeting were published, so the 2019 CSCO guidelines Recommended for upgrading to level II; 2020 ASCO-GI conference further updated at ATTRACTION-2 research follow-up data for 3 years; A approved for patients with advanced or recurrent gastric or gastroesophageal junction adenocarcinoma (G/GEJC) who have received two or more systemic treatment options in the past, becoming the first gastric cancer immunotherapy drug in China. The 2020 CSCO guidelines once again raised the recommended level of Navuliu sing-ile at the highest level of I, and Navuliu supres the first immunoostine point inhibitor to enter the grade I recommended for gastric cancer treatment.
As China's most influential cancer academic organization, CSCO's guidelines for the diagnosis and treatment of malignant tumors have played a key role in promoting the standardization of cancer diagnosis and treatment in China, and the 2020 edition of the CSCO Guidelines for the Diagnosis and Treatment of Gastric Cancer Taking into account regional development differences, the accessability of drugs and diagnostic methods, and the social value of tumor treatment, the general diagnosis and treatment measures with high level of evidence and good access, the relative stability of the value of tumor treatment and the drugs included in the basic national medical insurance are included in the I.-level recommendation.
based on the above criteria, Navuliu monoto-resistance at the highest level (Grade I) recommended for gastric cancer third-line treatment, is a matter of popular concern.
previously, only Apatinib received Grade I recommendations in the CSCO Gastric Cancer Guidelines for the third-line treatment of advanced gastric cancer.
Navuliumono became the first immunological checkpoint inhibitor to enter Class I recommended.
ATTRACTION-2 is a randomized, double-blind, placebo-controlled Phase III study conducted in Asia that establishes for the first time the effectiveness and safety of immunotherapy for gastric cancer. the
study included 493 patients from Taiwan, Japan, and South Korea, aged 20 with non-excisible advanced or recurrent gastric or gastroesophageal junction cancer, who were ineffective or intolerant to standard treatment (having previously received two or more chemotherapy options) and were randomly treated with Navriyu monotherapy (n-330) or placebo (n-163) at a 2:1 ratio.
study endpoint is Total Survival (OS).
2018 ESMO conference, researchers presented two-year follow-up results from the ATTRACTION-2 study, showing significant improvements in OS in the Navulyu monoa resistance group.
of the 493 patients in the total group, the median OS in the Navuliu monototheliated group and the placebo group were 5.26 months and 4.14 months, respectively, with 1-year OS rates of 27.3% and 11.6%, and 2 years of OS, respectively. The rates were 10.6% and 3.2%, respectively, and Navuliu single resistance reduced the risk of death by 38% (HR.62, 95% CI 0.51 to 0.76, P 0.0001; Figure 2).
follow-up data presented at the 2020 ASCO-GI conference showed that the three-year OS rates of the Navulyu monoantigen group and the placebo group were 5.6% and 1.9%, respectively, compared with the Navulyu monoantigen group. The placebo group significantly reduced the risk of death by 38% (HR-0.62, 95% CI 0.50-0.75, P.lt;0.0001).
15 patients in the Navulyu monotherapy group and 3 patients in the placebo group survived for more than 3 years, respectively, and 2 of the 3 patients in the placebo group subsequently received Navulyu monotherapy.
noteworthy, the navulyu monotherapy group reached total remission (CR) or partial remission (PR) in patients with a medium OS of 26.68 months and a three-year OS rate of 35.5%.
the safety of Navuliu monotomatore in this study, consistent with the safety reported in previous clinical trials of other solid tumors, confirmed the safety of Navuliu monotomatherapy.
in 330 patients treated with Navuliu monobresistance, the median OS was about 2 times that of patients without TRAE (7.95 vs 3.81 months) and the 3-year OS rate of these patients was more than 10%.
the ATTRACTION-2 study in Taiwan, China, released at the 2019 CSCO Conference, showed that the efficacy and safety results of Navuliu monotoreactor were basically consistent with the overall population data.
20% vs 0% vs 10% vs 0% for the placebo group compared to the Navulyu monoantigen group, and 5.06 vs 4.11 months for the two groups, respectively.
the Navulyu monothesity group had a 51 percent lower risk of death than the placebo group and a lower risk of death than the overall population (38 percent).
, stomach cancer is an important disease burden with "Chinese characteristics", and it is worrying that the vast majority of gastric cancer patients are in advanced stages at the time of discovery.
The CSCO Guidelines for The Diagnosis and Treatment of Gastric Cancer, as an authoritative guide suitable for china, are of great significance to the clinical practice of Chinese doctors, and this guide, combined with evidence-based medical evidence and annual updates of Chinese clinical practice, ensures that the guidelines are time-effective and clinically operability-
and Navuliu singular resistance to I grade recommended in the 2020 edition of the "CSCO gastric cancer diagnosis and treatment guide", marking that it has become a new standard of gastric cancer treatment, opened a new chapter in the treatment of gastric cancer in such patients, but also solidified the treatment status of immunotherapy in advanced gastric cancer! Jelly Source: Tumor Information, !-- End of Content Presentation -- !-- Determine stoate at end.